

15 - References

References

Depression and anxiety disorders CHAPTER 3 References

1. Furukawa TA, et al. Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review. *BMJ* 2002; 325:991.
2. Donoghue J, et al. Suboptimal use of antidepressants in the treatment of depression. *CNS Drugs* 2000; 13:365-368.
3. Lancaster SG, et al. Lofepramine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. *Drugs* 1989; 37:123-140.
4. Montgomery SA, et al. The optimal dosing regimen for citalopram: a meta-analysis of nine placebo-controlled studies. *Int Clin Psychopharmacol* 1994; 9 Suppl 1:35-40.
5. Burke WJ, et al. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. *J Clin Psychiatry* 2002; 63:331-336.
6. Altamura AC, et al. The evidence for 20mg a day of fluoxetine as the optimal dose in the treatment of depression. *Br J Psychiatry Suppl* 1988; (3):109-112.
7. Walczak DD, et al. The oral dose-effect relationship for fluvoxamine: a fixed-dose comparison against placebo in depressed outpatients. *Ann Clin Psychiatry* 1996; 8:139-151.
8. Dunner DL, et al. Optimal dose regimen for paroxetine. *J Clin Psychiatry* 1992; 53 Suppl:21-26.
9. Moon CAL, et al. A double-blind comparison of sertraline and clomipramine in the treatment of major depressive disorder and associative anxiety in general practice. *J Psychopharmacol* 1994; 8:171-176.
10. Loo H, et al. Determination of the dose of agomelatine, a melatonergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. *Int Clin Psychopharmacol* 2002; 17:239-247.
11. Hewett K, et al. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. *J Psychopharmacol* 2009; 23:531-538.
12. Kornstein SG, et al. The effect of desvenlafaxine 50 mg/day on a subpopulation of anxious/depressed patients: a pooled analysis of seven randomized, placebo-controlled studies. *Hum Psychopharmacol* 2014; 29:492-501.
13. Iosifescu DV, et al. Efficacy and safety of axs-05 (dextromethorphan-bupropion) in patients with major depressive disorder: a phase 3 randomized clinical trial (GEMINI). *J Clin Psychiatry* 2022; 83:21m14345.

14. Goldstein DJ, et al. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. *J Clin Psychopharmacol* 2004; 24:389-399.
15. Detke MJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. *J Clin Psychiatry* 2002; 63:308-315.
16. Phillips B, et al. Gepirone: A new extended-release oral selective serotonin receptor agonist for major depressive disorder. *J Pharm Technol* 2024; 40:230-235.
17. He H, et al. Efficacy and tolerability of different doses of three new antidepressants for treating major depressive disorder: a PRISMA-compliant meta-analysis. *J Psychiatr Res* 2018; 96:247-259.
18. Furukawa TA, et al. No benefit from flexible titration above minimum licensed dose in prescribing antidepressants for major depression: systematic review. *Acta Psychiatr Scand* 2020; 141:401-409.
19. Priest RG, et al. Moclobemide in the treatment of depression. *Rev Contemp Pharmacother* 1994; 5:35-43.
20. Schatzberg AF. Clinical efficacy of reboxetine in major depression. *J Clin Psychiatry* 2000; 61 Suppl 10:31-38.
21. Brogden RN, et al. Trazodone: a review of its pharmacological properties and therapeutic use in depression and anxiety. *Drugs* 1981; 21:401-429.
22. Feighner JP, et al. Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients. *J Affect Disord* 1998; 47:55-62.

Revision #1

Created 2026-01-04 20:15:17 UTC by Omar Ayman

Updated 2026-01-04 20:15:17 UTC by Omar Ayman